386 related articles for article (PubMed ID: 29691590)
1. Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity.
Fagnocchi L; Poli V; Zippo A
Cell Mol Life Sci; 2018 Jul; 75(14):2537-2555. PubMed ID: 29691590
[TBL] [Abstract][Full Text] [Related]
2. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
Wooten DJ; Quaranta V
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic plasticity of enhancers in cancer.
Yao J; Chen J; Li LY; Wu M
Transcription; 2020 Feb; 11(1):26-36. PubMed ID: 31944157
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN; Scaffidi P
Trends Cancer; 2017 May; 3(5):372-386. PubMed ID: 28718414
[TBL] [Abstract][Full Text] [Related]
5. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
6. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.
Zhou Z; Li J; Ousmane D; Peng L; Yuan X; Wang J
Mol Ther; 2024 Mar; 32(3):572-579. PubMed ID: 38327048
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis.
Chevet E; Hetz C; Samali A
Cancer Discov; 2015 Jun; 5(6):586-97. PubMed ID: 25977222
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Priming in Cancer Initiation.
Vicente-Dueñas C; Hauer J; Cobaleda C; Borkhardt A; Sánchez-García I
Trends Cancer; 2018 Jun; 4(6):408-417. PubMed ID: 29860985
[TBL] [Abstract][Full Text] [Related]
9. A step-by-step microRNA guide to cancer development and metastasis.
Markopoulos GS; Roupakia E; Tokamani M; Chavdoula E; Hatziapostolou M; Polytarchou C; Marcu KB; Papavassiliou AG; Sandaltzopoulos R; Kolettas E
Cell Oncol (Dordr); 2017 Aug; 40(4):303-339. PubMed ID: 28748501
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming in cancer.
Suvà ML; Riggi N; Bernstein BE
Science; 2013 Mar; 339(6127):1567-70. PubMed ID: 23539597
[TBL] [Abstract][Full Text] [Related]
11. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
12. Enhancer engagement sustains oncogenic transformation and progression of B-cell precursor acute lymphoblastic leukemia.
Corleone G; Sorino C; Caforio M; Di Giovenale S; De Nicola F; Goeman F; Bertaina V; Pitisci A; Cortile C; Locatelli F; Folgiero V; Fanciulli M
J Exp Clin Cancer Res; 2024 Jun; 43(1):179. PubMed ID: 38926853
[TBL] [Abstract][Full Text] [Related]
13. Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticity.
Huyghe A; Furlan G; Schroeder J; Cascales E; Trajkova A; Ruel M; Stüder F; Larcombe M; Yang Sun YB; Mugnier F; De Matteo L; Baygin A; Wang J; Yu Y; Rama N; Gibert B; Kielbassa J; Tonon L; Wajda P; Gadot N; Brevet M; Siouda M; Mulligan P; Dante R; Liu P; Gronemeyer H; Mendoza-Parra M; Polo JM; Lavial F
Nat Cell Biol; 2022 Sep; 24(9):1350-1363. PubMed ID: 36075976
[TBL] [Abstract][Full Text] [Related]
14. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
15. Cancer cell plasticity: Impact on tumor progression and therapy response.
da Silva-Diz V; Lorenzo-Sanz L; Bernat-Peguera A; Lopez-Cerda M; Muñoz P
Semin Cancer Biol; 2018 Dec; 53():48-58. PubMed ID: 30130663
[TBL] [Abstract][Full Text] [Related]
16. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Yamada Y; Yamada Y
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
18. Current status in cancer cell reprogramming and its clinical implications.
Izgi K; Canatan H; Iskender B
J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
[TBL] [Abstract][Full Text] [Related]
19. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
20. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
